Every material Form 8-K Bristol Myers Squibb filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bristol Myers Squibb said holders tendered enough notes by the November 17, 2025 early deadline to exhaust its amended purchase limits, so it will accept all validly tendered Pool 1 notes and most Pool 2 notes and will settle on November 20, 2025. The filing says no later tenders will be accepted, and the company is retiring the purchased notes, which reduces its outstanding debt.
Amended Pool 1 maximum is approximately $3.99 billion, down from $4.0 billion; all validly tendered Pool 1 notes were accepted at 100% proration
Amended Pool 2 maximum is approximately $3.51 billion, up from $3.0 billion; notes with priority levels 1 through 4 were accepted in full, and $250 million of the 5.900% notes due 2033 were accepted at a 50.84% proration factor
Early Settlement Date is November 20, 2025; the offers were set to expire December 3, 2025, but no final settlement is expected
On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company, a wholly owned subsidiary, completed a public offering of five series of euro-denominated senior unsecured notes guaranteed by Bristol-Myers Squibb. The company plans to use the proceeds, together with approximately $3.0 billion of cash on hand, mainly to fund a tender offer for various series of its outstanding notes, with any remaining proceeds for general corporate purposes. For shareholders, the filing shows a debt refinancing that reshapes the maturity profile rather than a change in operations.
Five series totaling €5.0 billion: €750 million due 2030, €1.15 billion due 2033, €1.15 billion due 2038, €750 million due 2045, and €1.2 billion due 2055
Coupons range from 2.973% (2030 Notes) to 4.581% (2055 Notes), with interest payable annually beginning November 10, 2026
Proceeds, plus about $3.0 billion of cash on hand, are earmarked for the tender offer for outstanding notes, fees and expenses, and general corporate purposes
Offering made under a prospectus supplement dated November 5, 2025 and an underwriting agreement dated November 5, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bristol Myers Squibb filing is on SEC EDGAR ↗. 8-K briefs of other companies →